Tuesday 16 June 2026

One To Watch

Remix Therapeutics

A clinical stage biotech company developing novel small molecule therapies designed to reprogram RNA processing and treat disease.

Company Overview

Want to Update your Company's Profile?


Latest Remix Therapeutics News

Remix Therapeutics promotes Dominic Reynolds to CSO post
1 February 2024
Remix Therapeutics enters collaboration with Roche
3 January 2024
Janssen collaborates with Remix to advance small molecule therapeutics
17 February 2022
More Remix Therapeutics news >


Today's issue

Reunion Neuroscience names Sahil Kirpekar as new CEO
Biotechnology
Reunion Neuroscience names Sahil Kirpekar as new CEO
16 June 2026
Pharmaceutical
Russia may revise patent protection terms for original drugs
16 June 2026
Biotechnology
Vivoryon’s kidney reset: CEO Frank Weber on the company’s new focus
15 June 2026
Pharmaceutical
Grifols launches Fesilty in USA for rare bleeding disorder
15 June 2026
Biotechnology
Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study
15 June 2026
Pharmaceutical
Two-year data bolster Neurocrine’s Crenessity case in pediatric CAH
15 June 2026
Biotechnology
J&J’s Talvey combo cuts progression risk in earlier myeloma setting
15 June 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze